
Tag: Tremelimumab

Characteristics of long-term survivors in the CASPIAN trial


HIMALAYA: Durvalumab ± tremelimumab new first-line option for unresectable HCC


Three-year OS follow-up from CASPIAN trial
Durvalumab ± tremelimumab by cisplatin eligibility in metastatic urothelial carcinoma

ES-SCLC: CASPIAN trial perspectives from Prof. Jonathan Goldman
Better prediction of favourable responses to immune checkpoint inhibitors in mUC

ES-SCLC: tremelimumab + durvalumab + chemotherapy misses endpoint

I-O monotherapy
